Latest news with #ISO-certified
Business Insider
5 hours ago
- Business
- Business Insider
The footwear capital, Abia State, in strategic talks with Yikodeen, West Africa's footwear giant on 10,000-pair daily capacity factory
In a strategic move poised to redefine Africa's manufacturing narrative, Yikodeen Company Limited, the largest safety footwear manufacturer in West Africa, is in high-level discussions with the Government of Abia State on the establishment of a state-of-the-art footwear factory in Aba, Nigeria's renowned footwear capital. This proposed partnership between the Abia State Government and Yikodeen will see the development of a world-class manufacturing facility capable of producing 10,000 pairs of footwear per day, forming the Eastern anchor of Yikodeen's national expansion plan to hit a total of 20,000 pairs daily. The talks are spearheaded by His Excellency, Dr. Alex Otti, Executive Governor of Abia State, who hosted Yikodeen's Founder and CEO, Mr. Shamsideen Atunde, at his country home in a meeting that has been described as visionary and deeply inspiring. Yikodeen is a proudly indigenous company with a proven track record of excellence in industrial footwear production. From humble beginnings in 2016, producing just 20 pairs daily, the company has grown into Nigeria's foremost safety footwear manufacturer and largest single exporter of made-in-Nigeria footwear, supplying European markets and global brands. The company's factory in Lagos, Yikodeen Factory 2.0, was recently recommissioned and now stands as the largest in Sub-Saharan Africa, with a production capacity of 2,500 pairs per day. This ultra-modern, ISO-certified facility includes automated QA/QC systems, advanced European machinery, and a skilled workforce of over 350 Nigerians. As a testament to its commitment to domestic industrialisation, Yikodeen also partners with the Lagos State Ministry of Wealth Creation through a dedicated Leather Hub, a 1,000-pairs-per-day facility designed to boost job creation, promote local content, and drive export readiness. Mr. Atunde, reflecting on his visit to Abia State, stated: 'Abia's transformation is undeniable. The Governor's compassion, clarity of vision, and commitment to local development truly moved me. Aba has long been the heartbeat of Nigeria's indigenous footwear craftsmanship. By marrying this legacy with Yikodeen's technology, standards, and global distribution network, we can elevate Aba into a true global industrial hub. My interaction with the Governor gave me renewed hope — that Nigeria can, and indeed will, be great.' The proposed 10,000-pair-per-day facility in Aba will include multi-line production for industrial safety boots, military and paramilitary footwear, school sandals, and slippers. It will be designed with training spaces to upskill over 2,500 local artisans annually, embed international QA/QC systems, and connect directly to Yikodeen's export pipeline. The company is already in advanced talks with international procurement partners looking to increase sourcing from Africa, and the Aba facility will be a key enabler of this ambition. The socio-economic impact of the project is expected to be significant: 2,500 direct jobs for skilled and semi-skilled workers. 2,000 indirect jobs in logistics, maintenance, raw materials supply, and services. Over $20 million in economic activity within two years. Increased use of local leather, rubber, and packaging. Aba-branded products exported under the Made in Nigeria label. A pipeline for youth employment, internships, and entrepreneurship. The partnership is part of Yikodeen's broader vision to establish a pan-African footprint, with upcoming facilities also being developed in Kaduna (to serve military and paramilitary needs) and Ghana (in collaboration with the government). These investments are designed to scale Nigerian manufacturing leadership in footwear across the continent and reduce Africa's dependency on imported personal protective equipment. For Abia State, which has long been the cultural and industrial nucleus of Nigeria's footwear industry, this partnership presents a unique opportunity to institutionalize excellence, formalize artisan networks, and transform local ingenuity into globally competitive manufacturing. 'Governor Otti's administration is focused on rebuilding Aba not just as a market, but as a factory to the world,' said a government representative familiar with the discussions. 'Yikodeen is the right partner at the right time — their success story speaks for itself, and this collaboration aligns with our ambition to industrialise Abia at scale.' The discussions are ongoing, with joint technical assessments already being scheduled to identify suitable land, infrastructure, and logistics requirements for the project. The parties are optimistic that a formal Memorandum of Understanding (MoU) will be signed in the coming weeks. At its core, this initiative is more than just an industrial expansion, it is a bold statement about African self-reliance, ingenuity, and economic transformation. With Yikodeen's expertise and Abia's unmatched footwear legacy, a new chapter in Africa's manufacturing history is about to begin, with Aba and Nigeria leading the charge. About Yikodeen Yikodeen Company Limited is Nigeria's leading safety footwear manufacturer, producing protective and performance-driven footwear for industries across oil & gas, construction, agriculture, education, and security. Certified by the Nigerian Content Development and Monitoring Board (NCDMB) and trusted by major corporations, Yikodeen stands as a homegrown champion of industrial excellence, local content, and inclusive economic growth.
&w=3840&q=100)
Business Standard
a day ago
- Business
- Business Standard
Quality Power shares zoom 6% on bagging ₹10 crore worth export order
Shares of Quality Power Electrical Equipments rose over 6 per cent on Tuesday after it bagged an export order worth ₹10 crore for a hyperscale data centre project in Finland. The heavy electrical equipment firm's stock rose as much as 6.3 per cent during the day to ₹869.9 per share. The stock pared gains to trade 4.14 per cent higher at ₹861 apiece, compared to a 0.02 per cent advance in Nifty 50 as of 10:50 AM. Shares of the company are trading near their all-time high of ₹931.4, which it hit on July 18. The counter has risen nearly 100 per cent since its listing in February this year. Quality Power has a total market capitalisation of ₹6,722.15 crore. Track LIVE Stock Market Updates Here Quality Power bags over ₹10 crore export order The company secured an export order worth over ₹10 crore from a European client for a hyperscale data centre project in Finland, according to an exchange filing. The order involves the supply of dry-type shunt reactors, marking a significant milestone in the company's global expansion and growing role in critical power infrastructure for digital facilities. The reactors, based on Quality Power's advanced air-core coil technology, are designed to stabilise voltage and control reactive power under light load conditions, ensuring grid stability and power quality at the utility interface. These solutions are especially relevant for data centres in colder European climates, where power factor correction and voltage regulation are increasingly critical, the company said. The equipment complies with IEC 60076-6 and relevant data centre resilience standards. Dry-type reactors are preferred in sensitive environments due to their lower fire and environmental risk compared to oil-filled alternatives. Manufacturing and testing will take place at Quality Power's ISO-certified coil facility in Sangli, Maharashtra, and the execution of the order will begin immediately, the statement said. About Quality Power The company is a manufacturer of high-voltage electrical equipment and solutions, providing reactors, transformers, line traps, FACTS, and power quality solutions. With multiple manufacturing facilities in India and Turkey, the company has installations in over 100 countries for equipment up to 765kV systems. The company's shares made their D-street debut on February 24, 2025, by listing at Rs 430 per share on the NSE, and Rs 432.05 per share on the BSE, against the IPO issue price of Rs 425 per share.
Business Upturn
a day ago
- Business
- Business Upturn
Quality Power Electrical shares jump 2% after bagging Rs 10 crore export order for Microsoft-linked Finland data centre
By Aditya Bhagchandani Published on July 22, 2025, 09:43 IST Shares of Quality Power Electrical Equipments Ltd rose over 2% today after the company announced it has secured a significant export order from a leading European customer for a hyperscale data centre project in Finland, reportedly associated with Microsoft. The company disclosed in its regulatory filing that it has won an order worth approximately ₹10 crore to supply dry-type Shunt Reactors, which will be manufactured at its ISO-certified facility in Sangli, India. The order is expected to be completed within 12 months and marks a strategic entry into the data centre segment for the company. These dry-type air core Shunt Reactors, compliant with IEC 60076-6 standards, are designed to stabilize voltage and manage reactive power in sensitive, high-performance environments like hyperscale data centres. Unlike oil-filled alternatives, these reactors offer reduced fire and environmental risks, making them ideal for mission-critical infrastructure. Commenting on the development, Vivek Moroney, President – Operations, said: 'Securing this order following rigorous technical evaluations by Scandinavian utilities and consultants reaffirms our engineering capabilities and growing presence in global markets. This strategic entry into supplying for large-scale data centre applications strengthens our position internationally.' At the time of writing, shares of Quality Power Electrical Equipments Ltd were trading at ₹844.85, up 2.18% on the NSE. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Time Business News
3 days ago
- Business
- Time Business News
Pharma & Research Laboratories in Canada
Canada is recognized as a world leader in pharmaceutical research, development, and innovation. Highly equipped Pharmaceutical Laboratories and a regulatory structure that favours growth give the country a leading edge in medical and biotech advances. If you are a pharmaceutical company, healthcare provider, or a biotech start-up, the potential for partnerships with a reputable Canadian lab is both broad and profound. Pharmaceutical laboratories play a crucial role in developing safe and effective drugs and treatments for patients. These laboratories are key to: Conducting clinical research and trials. Developing new drugs and formulations. Maintaining compliance with quality standards and regulations. Advancing vaccine and biotechnology research. There are numerous reasons the world owes Pharma Laboratories a great debt for the company's significant contributions to public health. They are the unsung heroes of modern medicine, from cancer research to vaccine development. Lab Canada has been expanding at an unprecedented pace in the last few years. With strong government support, significant investment in research and development, and a highly skilled workforce, Canadian labs are making notable strides in pharmaceutical science. Canada is listed as one of the world's leaders in clinical trials, biologics research, and biotech innovation. The Canada lab has some of the best good manufacturing practices (GMP-compliant) and technology in the industry, which is unmatched anywhere. Many of these labs are also ISO-certified, meaning they adhere to international quality standards and maintain a safe testing environment. Most Canadian Pharmaceutical Laboratories Offer services that cater to all aspects of the pharmaceutical development cycle. These include: Analytical Services: Analysis for chemicals, stability testing, and testing of raw materials. Analysis for chemicals, stability testing, and testing of raw materials. Formulation: Dosage formulation including tablets, capsules, AND injectables, etc. Dosage formulation including tablets, capsules, AND injectables, etc. Microbiology Testing: Testing for harmful microorganisms in products. Testing for harmful microorganisms in products. Regulatory Submission: Supply relevant information for regulatory filings. Supply relevant information for regulatory filings. Bioavailability & Bioequivalence Studies: Efficacy of the drug being compared with the standard. From small batch testing to vast pharmaceutical manufacturing, be assured that Canadian Analytical Laboratories is our trusted partner in innovation and dependability. When choosing a laboratory, reliability, compliance, and innovation are non-negotiable. Here are some reasons why getting a Canadian lab is a good business decision: Elite Level Standards: Canadian labs comply with Health Canada & FDA standards. Canadian labs comply with Health Canada & FDA standards. Cutting-edge Technology: These laboratories are equipped with the best-of-breed tools, from AI-powered analytics to robotics automation. These laboratories are equipped with the best-of-breed tools, from AI-powered analytics to robotics automation. Expertise & Talent: With highly educated chemists, biologists, and lab techs, quality is a given. With highly educated chemists, biologists, and lab techs, quality is a given. Nut Data Integrity: Security and accuracy should be maintained in all testing activities. Security and accuracy should be maintained in all testing activities. Teamwork: Easily collaborate with research and manufacturing teams worldwide. Pharma Labs also services more than drug manufacturers. These include: Biotechnology Companies Healthcare Providers Nutraceutical Brands Academic and Research Institutions Veterinary Medicine Providers From diagnostics to commercial production, Laboratories Canada delivers tailored services to different industries. Laboratory needs continue to evolve in response to global health threats. Canada is investing heavily in AI for diagnostics, personalized medicine, and green chemistry. The future of Pharma Laboratories in Canada is bright, sustainable, and innovative. In today's fast-paced world, having the right partner can make all the difference when developing innovative pharmaceutical products. Pharma Laboratories Canada upholds the highest standards of quality, innovation, and compliance among its partnered drug developers and industry professionals in the pharmaceutical, biotechnology, and healthcare sectors. Whether you're introducing a new drug or in the process of testing, having a Canadian laboratory means your project is in reliable hands. When it comes to Research and Development, Canada laboratory represents trust, effectiveness, and innovation. Q1. What are the services provided by Pharma Laboratories in Canada? A: They provide analytical testing, formulation development, microbiology testing, support for clinical trials, and regulatory consulting. Q2. Do Canadian laboratories meet the international standard? A: Yes, most Canadian labs comply with GMP, ISO certifications, and follow FDA and Health Canada regulations. Q3. How Do I Find the Best Canadian Lab for My Project? A: Look at lab accreditation, experience, technology, turnaround times, and customer reviews. Q4. Do foreign pharmaceutical companies support Canadian labs? A: Absolutely, Canadian labs frequently partner with overseas clients and provide comprehensive services, including logistics, documentation, and regulatory applications. Q5. These labs are only for drugs? A: No, they additionally cater to the biotechnology, nutraceuticals, academic research, and veterinary sectors. TIME BUSINESS NEWS
Yahoo
5 days ago
- Business
- Yahoo
Jim Cramer Fuels D-Wave: What Awaits QBTS After 31% Rally in July?
Investor excitement around D-Wave Quantum Inc. QBTS reached new highs this week after CNBC's influencer market analyst Jim Cramer spotlighted the company on Mad Money, suggesting it was a compelling buy for those seeking exposure to the rapidly evolving quantum computing sector. The endorsement added fresh fuel to a stock already riding high on robust fundamentals and growing institutional interest. Following this, shares of QBTS jumped nearly 14% at yesterday's close. So far in July, the stock has soared 31.4%. (read more: Ahead of Q2 Earnings & Amid IBM, Google's Quantum Push, Is QBTS a Buy?) Image Source: Zacks Investment Research Meanwhile, D-Wave Quantum is gaining strong financial traction as it scales operations. In the first quarter of 2025, the company posted a remarkable 509% year-over-year revenue jump, driven by a $12.6 million Advantage2 system sale to Germany's Julich Supercomputing Center. This underscores D-Wave's evolving model blending high-value system sales with recurring revenues from its Quantum Computing-as-a-Service platform. Profitability metrics also improved. D-Wave posted a GAAP gross margin of 92.5%, achieved its lowest net loss since becoming a public company, and cut its adjusted EBITDA loss by 53% year over year, demonstrating meaningful operating leverage as revenues scaled up. In June, D-Wave raised $400 million through an at-the-market equity offering, priced at a 149% premium to its January raise, boosting cash reserves to $815 million. Management calls this the strongest balance sheet in the quantum sector, giving D-Wave ample power for acquisitions, R&D and cloud expansion. Case for D-Wave's Rivals Quantum Computing Inc. QUBT: In May 2025, QUBT launched its ISO-certified photonic chip foundry in Tempe, AZ, marking a key step toward full vertical integration. The facility has begun fulfilling pre-orders, with initial revenues expected to ramp up in 2026. In the first quarter of 2025, QUBT posted modest revenues of $39,000 and reported a $17 million non-cash gain, turning a profit. Management sees the foundry as a gateway to broader adoption across telecom, sensing and quantum computing markets. (Read more: QUBT Surges 175% in 3 Months: What's Next as Quantum Race Heats Up?) IonQ IONQ: In June 2025, IonQ accelerated its growth strategy with two major acquisitions. It acquired Lightsynq to enhance modular quantum architectures and support fault-tolerant networking. Days later, IonQ announced a $1.075 billion deal to acquire Oxford Ionics, integrating its ion-trap-on-a-chip technology to fast-track the development of compact, scalable systems. These moves strengthen IonQ's roadmap toward multi-million-qubit machines and global quantum deployment. 2025 Estimates for QBTS Improve Earnings estimates for D-Wave Quantum have improved from a loss of 25 cents per share to a loss of 19 cents for 2025 over the past 90 days. Image Source: Zacks Investment Research D-Wave Quantum currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Quantum Computing Inc. (QUBT) : Free Stock Analysis Report IonQ, Inc. (IONQ) : Free Stock Analysis Report D-Wave Quantum Inc. (QBTS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
